Literature DB >> 15169706

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.

Andrés Martin1, Lawrence Scahill, George M Anderson, Michael Aman, L Eugene Arnold, James McCracken, Christopher J McDougle, Elaine Tierney, Shirley Chuang, Benedetto Vitiello.   

Abstract

OBJECTIVE: The authors examined the developmental impact and temporal characteristics of risperidone-associated weight change.
METHOD: Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months. Change in serum leptin levels after 2 months was examined as a predictor of final weight gain in mixed regression models that controlled for site, gender, age, and risperidone dose.
RESULTS: Age- and gender-standardized weight increased after 6 months of treatment (gross: mean=5.6 kg [SD=3.9]; standardized: mean=0.6 z [SD=0.5]) and was positively correlated with weight gained after 1 month. Change in leptin levels after 2 months of treatment (mean=-0.3 ng/ml, SD=6.2) (N=48) did not predict final weight gain.
CONCLUSIONS: Chronic risperidone exposure in children with autism causes weight gain in excess of developmentally expected norms that follows a curvilinear trajectory and decelerates over time. Serum leptin change does not reliably predict risperidone-associated weight gain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15169706     DOI: 10.1176/appi.ajp.161.6.1125

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  38 in total

1.  First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

Authors:  Constadina Panagiotopoulos; Rebecca Ronsley; Dean Elbe; Jana Davidson; Derryck H Smith
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-05

2.  Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.

Authors:  Pieter J Hoekstra; Pieter W Troost; Bertine E Lahuis; Hans Mulder; Erik J Mulder; Barbara Franke; Jan K Buitelaar; George M Anderson; Lawrence Scahill; Ruud B Minderaa
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-12       Impact factor: 2.576

3.  Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.

Authors:  Logan K Wink; Maureen Early; Tori Schaefer; Amy Pottenger; Paul Horn; Christopher J McDougle; Craig A Erickson
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-02-24       Impact factor: 2.576

4.  Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder.

Authors:  Logan K Wink; Ryan Adams; Ernest V Pedapati; Kelli C Dominick; Emma Fox; Catherine Buck; Craig A Erickson
Journal:  J Autism Dev Disord       Date:  2017-07

Review 5.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  Current perspectives on physical activity and exercise recommendations for children and adolescents with autism spectrum disorders.

Authors:  Sudha M Srinivasan; Linda S Pescatello; Anjana N Bhat
Journal:  Phys Ther       Date:  2014-02-13

Review 7.  Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials.

Authors:  Peter S Jensen; Jan Buitelaar; Gahan J Pandina; Carin Binder; Magali Haas
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-10-30       Impact factor: 4.785

8.  Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.

Authors:  Kimberly A Stigler; Jonathan T Diener; Arlene E Kohn; Lang Li; Craig A Erickson; David J Posey; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

Review 9.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Authors:  Hua Jin; Jonathan M Meyer; Sunder Mudaliar; Dilip V Jeste
Journal:  Schizophr Res       Date:  2008-01-18       Impact factor: 4.939

10.  Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems.

Authors:  Devon Carroll; Victoria Hallett; Christopher J McDougle; Michael G Aman; James T McCracken; Elaine Tierney; L Eugene Arnold; Denis G Sukhodolsky; Luc Lecavalier; Benjamin L Handen; Naomi Swiezy; Cynthia Johnson; Karen Bearss; Benedetto Vitiello; Lawrence Scahill
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.